Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie 
Welcome,         Profile    Billing    Logout  
 8 Diseases   1 Trial   1 Trial   219 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
CodeBreaK 301, NCT06252649: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Recruiting
3
450
Europe, Japan, US, RoW
FOLFIRI Regimen, Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Bevacizumab-awwb, MVASI
Amgen
Metastatic Colorectal Cancer
09/27
04/31
NCT05180422: A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Withdrawn
1/2
43
US
AMG 510, MVASI
Criterium, Inc., Amgen
Non Small Cell Lung Cancer
01/23
01/23

Download Options